Table 1. Patient characteristics (N=112).

Numbers represent n (%) or median (interquartile range)

Age at urology visit, years	68 (61, 75)
Total PSA (ng/mL)	15.9 (8.1, 62.3)
<10	40 (36%)
10-20	22 (20%)
20-100	30 (27%)
100+	20 (18%)
Biopsy Gleason score category
6	1 (1%)
3+4	19 (17%)
4+3	7 (6%)
8	15 (13%)
9-10	70 (63%)
Clinical T stage
T1	28 (25%)
T2	23 (20.5%)
T3	34 (30%)
T4	14 (12.5%)
TX/Missing	13 (12%)
Risk group*
Low	0 (0%)
Intermediate	22 (20%)
High	34 (30%)
Locally advanced	17 (15%)
Metastatic	39 (35%)

^*Risk groups defined according to the NCCN criteria as: Low risk: T0, T1c, T2a and GS ≤ 6 and PSA < 10; Intermediate risk: T2, T2b, T2c or GS 7 or PSA 10-20; High risk: T3, T3a or GS 8-10 or PSA ≥ 20; Locally advanced: T3b-c, T4; Metastatic: N1 or M1.